Skip to content

Effects of Glucose Insulin Potassium infusion on inflammatory markers in patients with acute heart failure

Effects of Glucose Insulin Potassium (GIK) infusion on serum Nt.Pro BNP and Hs-CRP levels in patients with acute heart failure

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201111238185N1
Enrollment
50
Registered
2011-12-14
Start date
2011-11-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute heart failure. Heart failure, unspecified

Interventions

Intervention 1: Intervention group: 1 cc/kg/h GIK solution with formula 300 g/l glucose, 80 meq/l potassium, 50 u/l insulin during 48h. Intervention 2: Control group:placebo-serum isotonic solution wi
Treatment - Drugs
Placebo
Intervention group: 1 cc/kg/h GIK solution with formula 300 g/l glucose, 80 meq/l potassium, 50 u/l insulin during 48h.
Control group:placebo-serum isotonic solution with equal volume and speed

Sponsors

Vice chancellor for research and technology, Kermanshah university of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criterias: All patients presenting as acute heart failure with left ventricular ejection fraction (LVEF) 40; Diabetes mellitus; Hypoglycemia; hyperkalemia; High Hs-CRP states including Infectious and Rheumatic diseases, cancers, Tissue damages, Burns and inflammatory bowel diseases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Hs-CRP. Timepoint: Before GIK administration, at 3rd and 5th days after GIK administration. Method of measurement: Blood test.;Nt Pro BNP. Timepoint: Before GIK administration, at 3rd and 5th days after GIK administration. Method of measurement: Blood test.

Secondary

MeasureTime frame
Inhospital death. Timepoint: During hospital-stay period. Method of measurement: On the basis of vital sign.;Ventricular arrhythmias. Timepoint: During hospital-stay period. Method of measurement: On the basis of cardiac monitoring.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbolfazl Enaami

Kermanshah university of medical sciences

Ab.Enaami@kums.ac.ir; Enaami.Ab@gmail.com+98 83 1836 2022

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026